AKABY ALK-abello A/S Sponsored ADRs

ALK-Abello A/S engages in the production and development of pharmaceutical products to prevent and treat allergies. It also manufactures tablet-based allergy vaccines for pollen, house dust mites, animals, and insect stings. Its treatment comprises allergy vaccines, emergency treatment, and allergy diagnostics. The company was founded by Poul Christian Krejner Tejn Barfod on June 9, 1923 and is headquartered in Horsholm, Denmark. This is an ADR of a company whose stock trades outside of the U.S. as the symbol DC:ALK-B.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$90.00    Pink
As of 08/09/2022     OTCMarkets

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  Denmark
Country of incorporation:  Denmark
IPO date:  09/05/2013
Outstanding shares:  1,012,836,000
Average volume:  0
Market cap:   $91,155,240,000
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy